Kim Chi, MD | Authors


Results of the LATITUDE Trial in High-Risk Metastatic Hormone-Naive Prostate Cancer

June 05, 2017

Kim Chi, MD, professor, University of British Columbia, discusses results of the phase III LATITUDE trial of androgen deprivation therapy with abiraterone acetate plus prednisone (Deltasone) or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.